To PP or not to PPthat is the question RW has to deal with . I'm pretty sure Ph 2 is an expensive endeavour so a PP at this SP level will dissapoint a few of us minority shareholders including me . If TLT , through some great NRs , manages to bring the SP up in the next two months then the dilution will be less .... good for some but still not good enough for me . I don't want the banksters to have another party at our expense . IMO a JV is well deserved for TLT , they have worked hard and long to reach this point . The clinical trial results are oustanding and unique , the research on GBM and LUNG are going in the exact same direction NMIBC is ... positive . In 2018 TLT will be entering Ph 2 on two continents and multiple sites , we need the expertize and bankroll of a major partner not a bankster and i think RW knows this and he can confidently prove his case to big pharma . He will knock it out of the ball park for us with a JV .
GLTA